The webinar will feature a presentation by Key Opinion Leader (KOL) Richard Béliveau, Ph.D. (Université du Québec à Montréal) who will discuss the science of receptor-mediated cancer therapy and the discovery of sortilin as a novel target in cancer treatment. Dr. Béliveau will be available to answer questions following the formal presentations.

Theratechnologies’ management team will also give an update on their oncology pipeline including TH1902, the Company’s lead investigational peptide-drug conjugate (PDC) stemming from its SORT1+ Technology™ in oncology. SORT1+ Technology is a new class of cancer treatment targeting all sortilin-expressing cancers by linking approved anticancer drugs to a proprietary peptide that specifically binds to the sortilin receptor. The PDC is internalized by the sortilin receptor and the therapeutic agent is released directly inside the cancer cell. TH1902 was granted fast track designation by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy and is currently being evaluated in a Phase 1 clinical trial.